. 2018 Sep 17;14(9):e1007290. doi: 10.1371/journal.ppat.1007290

Table 1. Patient demographics and clinical information for samples analyzed by RNA-Seq: Resolution group.

Patient Code	Sex	Age at infection	Ethnicity	rs12979860 IFNL4 genotype	HCV genotype	Testing interval (days)^a		Estimated days post-infection	ALT (U/L)	AST (U/L)	HCV viremia
R1	F	23	Indigenous^b	CC	ND^c	32
							Pre-infection	-196	29	33	-
							Early acute	16	199	80	+
							Late acute	105	42	61	+
							Follow up	503	31	57	-
R2	M	44	Caucasian	CC	1a	65
							Pre-infection	-114	23	34	-
							Early acute	33	25	36	+
							Follow up	340	28	38	-
R3	M	24	Caucasian	CC	3a	71
							Pre-infection	-35	29	37	-
							Early acute	48	458	334	+
							Late acute	126	18	26	-
							Follow up	392	21	40	-
R4	M	25	Caucasian	CC	1	84
							Pre-infection	-42	24	37	-
							Early acute	42	2076	1335	+
							Late acute	138	18	30	-
							Follow up	409	23	37	-
R5	F	38	Eastern European	CC	3a	84
							Pre-infection	-131	33	25	-
							Early acute	42	618	807	+
							Late acute	108	25	34	+
							Follow up	197	19	28	-
R6	M	47	Caucasian	CT	1a	91
							Pre-infection	-45	20	31	-
							Early acute	68	449	208	+
							Late acute	130	37	39	+
							Follow up	179	23	36	-

^a The interval (in days) between the last negative and first positive HCV qualitative RNA test available on record. Values do not necessarily coincide with the availability of research samples or research visits

^b The term Indigenous respectfully refers to the First Nations, Inuit, and Métis Peoples of Canada

^c ND: Not Done